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FOREWORD 
Over the past two years the World Bank has been undertaking, with a number of 
collaborators, a "Health Sector Priorities Review". The core of the Review is a series of papers on 
the public health significance of major clusters of diseases in the developing world and on the cost 
and effectiveness of currently available technologies for their prevention and case management. In 
addition, as part of the Review, a number of cross-cutting papers provide demographic background, 
discuss issues involved in setting priorities, and review illustrative areas of intervention. 
The Review undertakes two tasks simultaneously: (i) it shows, by extended example, that 
cost-effectiveness measures (of a rough-and-ready sort) can be potent tools for guiding resource 
allocation in the health sector; and (ii) it considers a much broader range of diseases (and associated 
interventions) than the communicable childhood diseases that have dominated analytical concern in 
public health in developing countries. By undertaking these tasks it provides a first systematic 
analysis of the disease control priorities appropriate to the increasingly diverse epidemiological 
conditions that developing countries face as a result of declining fertility and child mortality rates. 
While the Review does, we feel, provide valuable guidance on disease control priorities, including 
related priorities for international aid, it does not deal with equally important policy issues concerning 
infrastructure development or finance. 
This paper consists of one of the 37 papers resulting from the Health Sector Priorities 
Review. A complete list of the papers resulting from the Review may be found at the end of this 
document, and copies of the papers may be obtained by contacting the authors or writing to me at the 
address below. 
It is expected that many of the papers resulting from the Review will ultimately be published 
in a volume to be edited by Dean T. Jamison and W. Henry Mosley, but, until such a volume 
becomes available, the individual papers will constitute the Review's findings. In Paper HSPR-13 
Jamison and Mosley summarize and draw conclusions from the Review as a whole. 
The Review's conclusions, and those of the individual papers in it, do not, of course, 
necessarily reflect those of the World Bank. 
Anthony R. Measham, Chief 
Population, Health and Nutrition Division 
The World Bank 
Washington, D.C. 20433 
November, 1990 
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ACUTE RESPIRATORY INFECTION 
by 
Sally K. Stansfield and Donald S. Shepard 
1. Introduction to Acute Respiratory Infection 
1.1 Background 
Acute respiratory infection (ARI) is the most frequent illness globally and a leading cause 
of death in the developing world. Among children under five alone, four million deaths 
annually are ascribed to ARI, most of which are due to pneumonia. The 10 to 50-fold 
excess mortality due to pneumonia in developing countries suggests that there is ample 
room for improvement in addressing this important public health problem. However, the 
heterogeneity of the clinical presentations and causative organisms in ARI has hampered 
efforts to design simple and effective interventions. 
The classification and management of ARI in the industrialized world is founded on 
epidemiologic, radiologic and microbiologic data, in addition to clinical history and 
physical examination. ARI syndromes, which are complex clinical conditions of varying 
etiology and severity, are most frequently categorized on the basis of anatomical location. 
Common diagnostic categories for uncomplicated ARI with etiologic and clinical 
correlates are detailed in table 3.1. As suggested by this table, ARI includes the minor 
upper respiratory infections (URI) such as colds and sore throats in addition to the more 
serious (and potentially fatal) acute lower respiratory infections (ALRI) of pneumonia 
and bronchiolitis. 
Most of the studies of ARI from developing countries have been conducted among 
infants and children. Programs which have been developed to prevent or treat ARI have 
often focused exclusively on children, arguing that the principal opportunities to reduce 
ARI mortality are among children under five. Although adults, particularly the elderly, 
may benefit from preventive and therapeutic interventions, the major impact in reducing 
years of life lost (YLL) will be seen among infants and children. The data and strategies 
outlined in this chapter therefore focus primarily on children under five. 
1.2 Risk Factors for ARI 
Treatment of pneumonia clearly reduces ARI mortality, but the definitive solution to the 
problem of excess ARI deaths in less developed countries (LDCs) will ultimately be 
found in prevention of pneumonia. Although the epidemiologic data from the 
developing world are limited, a review of the available information suggests possible 
approaches to the reduction of ARI mortality through reducing the risk of pneumonia. 
Table 3.2 summarizes the following discussion of some of the known and suspected risks 
for pneumonia incidence and mortality. 
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Table 3.1 
Acute Respiratory Infections: 




Diagnosis Etiologies (months) ortality 
Upper Nasopharyngitis Viral No 
Respiratory 
Infections 
(coryza, colds) (various) 
Otitis media Bacterial 6-17 
(middle ear (pneumococcus, 
infection) H. influenzae) 
Phayngo- Viral 






Epiglottitis Bacterial 24-47 Yes 
(H. influenzae) 















Pneumonia Bacterial 24-35 Yes 
(pneumococcus, 









RISK FACTORS FOR PNEUMONIA 
Increased Incidence 
Age <2 years or >65 years 
Males 
Poor nutritional status 
Low birth weight 
Lack of breastfeeding 




Vitamin A deficiency 
Increased Case-Fatality 
Age <2 years or >65 years 
Low socioeconomic status 
Poor nutritional status 
Low birth weight 
Lack of breastfeeding 
Lack of maternal education 
Reduced health care access 
Crowding 
Underlying chronic disease 
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Aye and Sex. The incidence of ARI (most of which is URI) is inversely related to 
age, peaking at four to nine infections in each of the first two years of life, dropping to 
three to four by school age, and remaining at 2-3 per year for adults (Datta Banik, 1969; 
Kamath, 1969; Monto, 1974; Friej, 1977; Spika, 1989). However, the frequency of 
pneumonia and the case-fatality ratio are highest among both the very young and the 
very old (Bulla, 1978; Berman, 1983; Ngalikpima, 1983). Studies in several developing 
countries have demonstrated that pneumonia occurred 1.5 to 1.8 times as frequently 
among infants as among children two to fours years of age (Berman, 1985). There is a 
slightly increased incidence of both overall ARI and pneumonia among males (Bulla, 
1978; Berman, 1983; Narain, 1987; Selwyn, 1990), although female children have been 
observed to have a higher case-fatality ratio in some countries, probably due to poorer 
access and quality of care during illness episodes (Tupasi, 1990). 
Socioeconomic Status and Child-Rearing Practice. Low socioeconomic status and 
crowding have been well documented as risk factors for mild respiratory infections in the 
industrialized world. Studies in developing countries (Verma, 1981; Stansfield, 1987; 
Tupasi, 1988; Vathanophas, 1990; Borrero, 1990) have also demonstrated an increased 
frequency of pneumonia requiring hospitalization among persons from lower 
socioeconomic groups and in more crowded households. Aaby (1988) has suggested that 
crowding is a predictor of an increased case-fatality ratio due to measles, in addition to 
an increased risk of infection. 
Both poverty and crowding may, however, be proximate measures for other known or as 
yet unrecognized risk factors. For example, the frequent association of these factors with 
lower educational levels, poor nutrition, and certain child-care practices further 
confounds analysis of risks for ARI. Existing evidence suggests, however, that infants 
with restricted respiratory excursion of the chest wall due to obesity (Tracey, 1971) or 
swaddling (Yurdakok, 1990) may have increased risk of pneumonia. Family stress also 
increases the risk of infections such as pneumonia among both children and adults 
(Graham, 1990; Foulke, 1988), probably due to interference with immune competence 
(Kiecolt-Glaser, 1986). Although chilling is frequently cited as a risk factor for URI or 
pneumonia, most studies have have provided no evidence of this association (Jackson, 
1963; Douglas, 1968). 
Nutritional Status and Practices. Poor nutrition lowers both systemic and local 
defenses against ARI, including through reduction of the effectiveness of epithelial 
barriers, systemic immune responses and cough reflexes. Nutritional status is inversely 
related to both the incidence and the case-fatality ratio for pneumonia (Berman, 1983, 
1991; Pio, 1982; Kielmann, 1978; Sommer, 1983, 1984). Investigators have documented a 
12- to over 20-fold greater incidence of pneumonia in undernourished children when 
compared with children of normal weight for age (James, 1972; Herrero, 1983; Berman, 
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1983; Tupasi, 1988). Mortality due to each of these already more frequent episodes of 
pneumonia increases two to 13-fold for each decile below 80% weight for age (Escobar, 
1976; Kielmann, 1978; Tupasi, 1985). 
While nutritional deficiency diseases augment the chances of ARI episodes, so episodes 
of ARI contribute to nutritional deficiency, thus further increasing the risk of subsequent 
infection and death. A prospective study in The Gambia (Rowland, 1988) showed that 
pneumonia reduced weight gain in young children by 14.7 g/day of infection. Recurrent 
ARI episodes, as a principal cause of the weight shortfall during infancy, therefore 
progressively increase the risk of death due to other childhood diseases. 
Low birth weight (LBW), seen in 20-40% of infants in many developing countries, also 
increases the risk and case-fatality ratio of pneumonia. Recent studies (Datta, 1987; 
WHO, 1988a) have shown relative risks of mortality due to pneumonia which are 2.5 to 
eight-fold greater among LBW infants. Other than malaria and tobacco chewing, the 
only factors associated with LBW for which cause/effect relationships have been 
established in LDCs (and which are "modifiable over the short term") are pre-pregnancy 
weight, gestational weight gain, and caloric intake (WHO, 1987a). Short birth intervals, 
teenage pregnancy, certain genital infections, and arduous work after mid-pregnancy are 
other potentially modifiable factors associated with LBW. Although reduction of the 
incidence of LBW would be expected to reduce ARI mortality, no prospective studies 
have demonstrated the feasibility and effectiveness of interventions to address this 
important problem. 
The few well-conducted studies on infant feeding practices and the incidence of 
pneumonia demonstrate a protective effect of breastfeeding. The literature has suffered 
from wide variations in definitions, both of specific feeding practice and of ARI. 
Although several studies summarized in a review by Jason (1984) failed to document any 
protective effect of breastfeeding, others have found a two- to five-fold decreased 
incidence of (Chandra, 1979; Singhi, 1987) and decreased case-fatality ratio due to 
pneumonia (LePage, 1981). A more rigorous study in southern Brazil (Victora, 1987) 
demonstrated that infants who were completely weaned had 3.6 times the risk of death 
due to pneumonia when compared to breastfed infants. 
Vitamin A deficiency, which often accompanies protein-calorie malnutrition, results in 
keratinization of the respiratory epithelium and depression of immune response, thus 
presumably decreasing both local and systemic resistance to bacterial colonization and 
infection. However, the literature on vitamin A deficiency and its association with ARI 
morbidity and mortality is sparse and controversial. Two studies (Sommer 1983; 1984; 
Bloem, 1990) have suggested a two- to four-fold increase in the relative risk of ARI 
associated with serologic or ophthalmic signs of vitamin A deficiency. In the Sommer 
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study (1983), mortality in the clinically vitamin A deficient group was 8.6 times that in 
non-xerophthalmic children. 
Although one prospective study noted a 34% reduction in mortality among vitamin A- 
supplemented children (Sommer, 1983), the causes of death among these children were 
not documented. Vitamin A supplementation of children with severe pneumonia or 
measles has improved clinical outcome and reduced mortality (Barclay, 1987; Hussey, 
1990). Prospective studies of the effect of vitamin A supplementation in children from 
areas with endemic vitamin A deficiency (who are, therefore, presumed-to be sub- 
clinically deficient) have not, however, demonstrated an impact on ARI-specific morbidity 
or mortality (Rahmathullah, 1990, 1991; Vijayaraghavan, 1990). The effect of vitamin A 
supplementation on ARI-specific morbidity and mortality among children who are not 
clinically xerophthalmic remains speculative. 
Smoking and Air Pollution. There is a large and expanding literature from 
industrialized countries on the effects of active and passive smoking in increasing the 
risk of pneumonia. Investigators in both industrialized and developing countries have 
demonstated a 1.5 to four-fold increased incidence of pneumonia among smokers and 
among children whose parents smoke (Ekwo, 1983; Ware, 1984; Weiss, 1983; Pedreira, 
1985; Yue Chen, 1986; Burchfiel, 1986; Samet, 1987; Harlap, 1974; Connochie, 1986; 
Leeder, 1976; Lipsky, 1986; DHHS, 1989). Maternal smoking also predisposes to low 
birth weight (Martin, 1986; Ruben, 1986), thus increasing the risk of ALRI mortality for 
the infant after birth. There are no prospective data currently available from developing 
countries to establish that programs to reduce smoking will reduce ARI-specific mortality. 
However, the recent alarming increases in the numbers of persons who smoke in 
developing countries argue for prompt intervention, particularly since successful reduction 
of smoking may be expected to yield health benefits beyond the reduction of ARI 
morbidity and mortality. 
Exposure to both outdoor and indoor air pollution have been suspected to increase the 
risk of ARI in many developing countries (Kamat, 1980; UNEP, 1988; Chen, 1990). 
There is growing concern regarding the health effects of the products of combustion 
(including carbon monoxide, particulates, and sulfur and nitrogen dioxides) from cooking 
and heating fires. It has been estimated that 300 to 400 million people, mostly in the 
rural areas of developing countries, may be adversely affected by these organic fuel 
emissions (de Koning, 1985). Although there is a clear relationship between exposure to 
such emissions and chronic obstructive pulmonary disease (WHO, 1984a; Chen, 1990), 
the relation to pneumonia in the developing world is less well documented. 
Indoor particulate concentrations, probably the best single indicator of toxic (non- 
carcinogenic) effects, are 20 times higher in the villages of developing countries than in 
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households where two packs of cigarettes are smoked per day (Pandey, 1989a). Several 
studies in developing countries have suggested that an increased incidence of pneumonia 
associated with exposure to organic fuel emissions (Kossove, 1982; Sofoluwe, 1968; 
Honicky, 1985; Campbell, 1989a; Penna, 1991) although several studies have had 
problems with confounding variables such as socioeconomic status and crowding. One 
study in Nepal (Pandey, 1988; 1989b) has demonstrated that the number of episodes of 
life-threatening ALRI among children under two is directly proportional to the reported 
hours per day spent near the stove. Studies in the Gambia suggest that carriage on 
mother's back during cooking may predispose children to ALRI (Armstrong, 1991). 
Prospective trials are required to assess the efficacy of interventions such as 
improvements in stove design, improved ventilation and/or behavioral change to reduce 
exposure. 
1.3 Clinical Syndromes Causing ARI Mortality 
The predominant known causes of ARI mortality are bacterial and viral pneumonia, 
measles, and pertussis. Additional epidemiologic data are needed to characterize the 
importance of other clinical syndromes and etiologic agents, including diphtheria, 
bacterial pharyngitis, and the "opportunistic" viral and bacterial infections which are likely 
important causes of ALRI mortality among the very young, the very old, and those 
immunocompromised by AIDS or malnutrition. 
Pneumonia. Pneumonia is an inflammatory process of the pulmonary interstitial 
space or alveoli which may be diffuse or confined to lung segments or lobes. Clinically, 
patients with pneumonia most frequently present with cough and tachypnea (rapid 
breathing), while retractions (indrawing of the lower chest wall on inspiration) may also 
be present in more severe cases. Among neonates and younger infants, however, cough 
is often absent. 
Available information from developing countries suggests that over 75% of ARI deaths 
are caused by pneumonia, both bacterial and viral (Bulla, 1978; Berman, 1991). 
Microbiologic data is difficult to obtain and of variable quality, yet most investigators 
agree that the bulk of ARI mortality among both children and adults is due to 
pneumonias caused by two bacteria, Streptococcus pneumoniae and Haemophilus 
influenzae (Denny, 1983; Berman, 1983; Shann, 1984; Selwyn, 1990; WHO, 1991a). Viral 
agents which cause mortality due to pneumonia include respiratory syncytial virus (RSV), 
measles, parainfluenza, influenza, and adenovirus. Mixed viral and bacterial infections 
are frequently documented (Berman, 1991). Clinical malaria has also been found to 
coincide frequently with the clinical and radiologic diagnosis of pneumonia (Byass, 1991). 
10 
StansSeld/Shepard ARI 
Measles. Measles is a vaccine-preventable disease causing an acute febrile 
eruption which occurs naturally only in humans. The viral infection itself may result in 
any of several clinical syndromes, including croup, bronchitis, bronchiolitis, or even viral 
pneumonia, particularly in children immunocompromised by severe malnutrition. These 
manifestations may occur in the absence of the typical measles rash. Common 
complications of measles include growth faltering, chronic diarrhea, otitis media (middle 
ear infection), encephalitis, and pneumonia. Pneumonia, including primary measles 
pneumonia as well as superinfection by viruses and bacteria, is the most common 
complication of measles, and often represents the principal proximal cause of death. 
In unimmunized populations, epidemics occur in 2-3 year cycles with secondary attack 
rates exceeding 90% among susceptible household contacts (Keja, 1988). Although 
generally a disease of childhood, measles can occur at any age in susceptible populations. 
Infants in industrialized countries are not usually affected under the age of 6-8 months, 
presumably due to placentally transmitted maternal antibodies. However, in parts of 
Africa, 20-45% of children are infected with measles before they attain the recommended 
age for immmunization at nine months. 
Although improving immunization coverage progressively reduces infection rates, it was 
estimated in 1989 that there were 70 million annual cases of measles, and that 1.5 to 2 
million of those affected would die during the month following infection. Although 
generally a mild disease in temperate climates, an estimated 1 to 5 percent of all affected 
children in developing countries will die of measles or its complications. Children who 
survive the acute episode have an increased risk of mortality for weeks to months 
following infection. Most investigators, therefore, report deaths which occur within one 
month of the measles rash as "measles-associated". 
Due in part to such variations in methods of ascertaining deaths due to or associated 
with measles, the reported case-fatality ratios vary widely. Williams (1983) documented a 
5% case-fatality ratio during the acute phase of the disease, and a cumulative rate of 
15% during the 9 months following the rash. The case-fatality ratios obtained from 
prospective population-based studies range from 2% in Bangladesh to 34% in Guinea- 
Bissau (WHO, 1987b). Rates of 50% or more have been described in severely 
undernourished populations. It has been suggested, however, that deaths prevented by 
measles immunization will be "replaced" by deaths from other causes, such that measles 
immunization may prevent fewer deaths than these mortality ratios would suggest. 
Pertussis. The majority of cases of "whooping cough", or the pertussis syndrome, 
are vaccine-preventable infections due to Bordetella pertussis. The paroxysms of 
coughing, often asssociated with a characteristic inspiratory gasp (the whoop), may persist 
for 4-10 weeks. Pertussis is often associated with dehydration and weight loss; and 
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encephalitis is an occasional complication. Pneumonia, due either to the organism itself 
or to secondary bacterial infection, is the proximal cause of death in over 90% of cases. 
Although pertussis occurs endemically, it tends to produce epidemics every three to four 
years, with up to 90% of exposed susceptibles developing the disease (Muller, 1986; 
Broome, 1981). Incidence is higher among girls than boys. Population-based studies 
have suggested a annual incidence of 1-5% among children under 15, although infants 
have a 16% chance of infection in Kenya (Voorhoeve, 1977). The case-fatality ratio 
averages around 1%, although up to 15% of cases were fatal in studies in Uganda 
(Bwibo, 1971) and Santa Maria Cauque (Mats, 1978). The highest mortality is observed 
among females and children under two, with an estimated 500,000 to one million infant 
deaths annually due to pertussis (Muller, 1986; Keja, 1988). 
Diphtheria. The epidemiology of diphtheria in the developing world is poorly 
understood. Although the causative organism, CoMebacterium diphtheriae, is widely 
present in Africa, and over 96% of unimmunized adults are immune (Ikejani, 1961; 
Muyembe, 1972), there are few reported cases of this vaccine-preventable disease. It has 
been suggested that immunity may result from subclinical or misdiagnosed infections, an 
explanation supported by the finding of carriage of the organism in 4 to 9% of the 
population (Ikejani, 1961; Muyembe, 1972). 
There are no community-based studies, but data from hospitals suggest diphtheria may 
be an important cause of pharyngitis and "croup" (laryngotracheobronchitis). Of 180 
children hospitalized with respiratory infections in Colombia (Escobar, 1976), seven of 
the nine cases of croup were due to diphtheria. Investigators in The Gambia (Heyworth, 
1973) found evidence to suggest an annual incidence of 6 per 1000 children under five. 
Salih (1985) has reported epidemic diphtheria and suggests that it is one of the most 
important diseases of childhood in the Sudan. 
Pharvn eitis. Pharyngitis is an upper respiratory tract infection that is most 
commonly viral, and, therefore, self-limited. Bacterial pharyngitis, although less common, 
is of greater public health importance. Though acute bacterial pharyngitis (except due to 
diphtheria) is not a significant primary cause of mortality, acute rheumatic fever (ARF) is 
an occasional late complication of untreated pharyngitis caused by Group A beta- 
hemolytic streptococci (Strel2tococcus pyo enes). ARF has been reported at rates of 27 
to 100 per 100,000 per year (WHO, 1988a), although it is much less frequent in 
industrialized countries. Microscopic cardiac damage during ARF may progress over 
subsequent years, frequently causing incapacitation and, ultimately, death due to changes 
in cardiac function. 
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Antibiotic therapy of bacterial pharyngitis is recommended in industrialized countries to 
prevent ARF and other sequelae of streptococcal pharyngitis. Management of 
streptococcal pharyngitis has been controversial, however, and even less is known of the 
epidemiology of streptococcal disease to guide its management in the developing world 
(Markowitz, 1981). In view of additional concerns regarding the cost and insensitivity of 
the laboratory tests, and the lack of criteria to distinguish streptococcal pharyngitis on 
clinical grounds, it is currently difficult to establish a strategy for management of 
pharyngitis in developing countries which will effectively prevent post-streptococcal 
complications. Antibiotic prophylaxis for patients with a history of rheumatic fever has, 
therefore, been recommended as the most feasible strategy to prevent rheumatic heart 
disease in developing countries (WHO, 1988a). 
Other Causes of ARI Mortality. Additional causes of ARI mortality include viral 
bronchiolitis and epiglottitis. Bronchiolitis, especially that due to RSV and parainfluenza 
3, may be responsible for up to one third of ALRI among children under five, most of 
which occurs in infants (Cherian, 1990). The virology of these infections is apparently 
similar to that observed in industrialized countries (Selwyn, 1990). The difficulty of the 
laboratory techniques and lack of cost-effective measures for prevention and treatment of 
these infections have hampered efforts to address these important causes of mortality. 
Epiglottitis, primarily due to Haemophilus influenzae type b, is an occasional cause of 
death due to respiratory obstruction. Additional epidemiologic investigations are also 
needed to define the role of other organisms as causes of mortality due to pneumonia, 
including group B streptococcus, Chlamydia trachomatis and C. pneumoniae, 
Mycoplasma pneumoniae, Ureaplasma urealyticum and Pneumocystis carinii. These 
bacterial and parasitic pneumonias may be important causes of mortality, especially 
among neonates or persons immunocompromised, such as by malnutrition or AIDS. 
Tuberculosis and some helminthic infections may also present as pneumonia, and these 
more chronic infections are often distinguished clinically by their failure to respond to the 
usual antibiotic therapy. 
2. The Public Health Significance of Acute Respiratory Infection 
Compilation and comparison of results from investigations on the public health 
significance of ARI in different countries is all but prevented by wide variations in study 
design, case definitions and culture techniques. Meaningful comparison of study results is 
difficult, for example, when some investigators have used sensitive case definitions which 
include all coughs and colds, while others focus only on more severe ARI which comes to 
the attention of health care workers. 
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2.1 Current Levels and Trends in the Developing World 
Morbidity and Mortality Levels, circa 1985. The few well-conducted community- 
based prospective studies performed suggest that overall incidence of ARI in the 
developing world is similar to that observed in the industrialized world. Prevalence 
figures show that children spend from 22% to 40% of observed weeks with ARI, and 
from 1% to 14% of observed weeks with ALRI, such as pneumonia or bronchiolitis. 
ARI accounts for 20 to 40% of adult outpatient consultations and 20 to 60% among the 
pediatric populations. Twelve to 45% of pediatric admissions to hospitals are for ARI, 
while 20 to 30% of adult inpatients have been admitted for ARI treatment (Bulla, 1978; 
PAHO, 1980; Leowski, 1986). 
The reported incidence of ALRI varies widely, from country to country as well as with 
age and nutritional status. While the annual incidence of pneumonia is 3 to 4 percent in 
children under 5 in the industrialized countries, it ranges from 10 to 20 percent in most 
developing countries, reaching as high as 80 percent in populations with a high 
prevalence of malnutrition and LBW. In Papua New Guinea in 1972-1973, for example, 
there were 72 episodes per thousand children one to four years of age, and 1,074 
episodes per thousand infants (Riley, 1981). While an annual incidence of ALRI of 37 
per thousand children was observed among those of normal nutritional status in Costa 
Rica, the rate was 457.8 per thousand among malnourished children (Pio, 1982). 
The overall incidence of ARI, most of which is coughs and colds, is comparable to that in 
the industrialized world. The greater public health importance of ARI in less developed 
countries is manifest, however, in the increased frequency of lower tract infections, and 
the 10- to 50-fold increased disease-specific mortality rates (WHO, 1984b; Mohs, 1985; 
Camargos, 1989). Most vulnerable to death due to ARI are the very young and the very 
old. 
Of the estimated 15 million deaths occurring each year among children under five, 25 to 
30% are due to ARI. As the cause of approximately 4 million deaths annually among 
this age group alone, ARI often surpasses diarrhea in importance as a cause of mortality 
(Bulla, 1978; Balint, 1979; Shann, 1984; Pio, 1985; Spika, 1989). Pneumonia causes from 
2% to 8% of adult deaths in countries for which data are available (Hayes, 1989), 
ranking from second to tenth as a cause of death among the 15-64 year age group. 
Trends in the Period 1970 to 1985. Although surveillance data for overall ARI 
morbidity in the developing world are limited, it is likely that these rates have remained 
unchanged in the past 15-20 years, just as they have in the industrialized countries. 
Reductions in incidence of ARI due to improved immunization coverage (with measles, 
diphtheria, and pertussis vaccines) would have little impact on overall ARI incidence, as 
the frequency of viral upper respiratory infections would remain largely unchanged. 
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Pneumonia mortality, on the other hand, has been reduced significantly over the past 15 
to 20 years in the U.S. for all age groups except the elderly. Similar reductions in 
mortality would be expected in developing countries where the risk factors such as 
nutritional or socioeconomic status, immunization coverage and access to health care 
have improved. In many countries, however, ARI has increased in relative importance, 
frequently emerging as the first cause of childhood death where diarrheal disease 
mortality rates have been successfully reduced (Chen, 1980; Zimicli, 1988). ARI 
mortality has increased in relative importance even in settings where high coverage with 
measles immunization has been achieved (Zimicki, 1988; Greenwood, 1988). 
Data from industrialized countries suggests that changes in immunization policy may 
adversely affect disease incidence. With intensive control efforts, for example, the 
incidence of measles in the U.S. had fallen to the lowest level ever recorded in 1983. 
However, increasing outbreaks have been observed since 1984 when expenditures for 
immunization were reduced. A similar resurgence of pertussis incidence has been noted 
in countries where changes in public opinion or immunization policy have led to a 
reduction in immunization coverage. 
2.2 Possible Patterns of Morbidity and Mortality in 2000 and 2015 
As viral upper resiratory infections, which account for the bulk of ARI morbidity, are 
unlikely to be eradicated in the foreseeable future, overall incidence of ARI is likely to 
be substantially unchanged over the next 25 years. Considerable opportunity exists, 
however, to reduce the incidence of vaccine-preventable ARI and to reduce the case- 
fatality ratio for pneumonia, thereby reducing ARI mortality. 
Changing demographic patterns, such as through improved birth spacing and consequent 
improvements in nutritional status, would be expected to substantially reduce mortality 
due to pneumonia over the next 25 years. Increased life expectancies may later create 
larger populations of the elderly, among whom pneumonia will likely remain a significant 
cause of mortality. Progress in improving the access to and quality of care will be 
instrumental in controlling mortality among both the young and the elderly. 
Of potential future concern, however, is the evolution of antimicrobial resistance among 
the pathogens causing bacterial pneumonia, which may interfere with the effectiveness of 
case management interventions. Although the development of newer antimicrobials has, 
to date, kept pace with the evolution of resistance, costs of later generation antibiotics 
will not be so easily borne in developing countries. And there is evidence to suggest that 
inappropriate use of antimicrobials, so frequent throughout the world, speeds the 
evolution of resistance. 
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Coverage with the vaccines currently included in WHO's Expanded Programme on 
Immunization (EPI) may be expected to continue to increase, also leading to reduction in 
ARI mortality. Improved vaccine technology will also likely alter the currently observed 
patterns of mortality due to ARI over these next 25 years. New vaccines may further 
improve hopes of reducing childhood ARI mortality due to measles and bacterial 
pneumonias caused by S. pneumoniae and H. influenzae. 
2.3 Economic Costs of ARI 
Direct Costs. ARI accounts for an average of 35% of all outpatient visits globally 
(Bulla, 1978), and generally similar proportions of all hospitalizations among children. 
The minimal direct cost of ALRI for children in the first two years of life in the US has 
been estimated at US$35.14 per child, fifty-six percent of which is attributable to 
hospitalization (McConnochie, 1988). 
In many developing coutries, the economic burden of treatment of ARI already exceeds 
the expected cost of ARI case management with improved effectiveness and broader 
coverage. More appropriate use of existing health personnel and pharmaceutical 
resources might be expected, in many countries, to avert mortality with little or no 
additional expenditure. For example, the prevalence of the inappropriate use of 
pharmaceuticals for the management of ARI suggests that a net cost savings might be 
achieved by improving use patterns (Stansfield, 1990; Foreit, 1991). Frequently, over half 
.)f antibiotic use is unnecessary (Quick, 1988; Stein, 1984; Hossain, 1982). A study in 
Peru (Foreit, 1987) showed that approximately 50% of the expenditures for medications 
to treat ARI episodes were inappropriate, at an excess cost of US$18.47 to $21.97 per 
child covered. They estimated that an 89% reduction in treatment costs would be 
achieved through altering outpatient treatment of ARI to conform to WHO guidelines. 
Both inappropriate prescription of antibiotics and poor compliance probably also 
contribute to the development of antimicrobial resistance, which will greatly increase the 
future direct costs of ARI treatment as the use of more expensive antimicrobial agents 
becomes necessary. 
Indrect Costs. ARI accounts for an average of one third of all absences from 
work (Bulla, 1978). In Britain, 1-2 weeks of schooling are lost per child per year due to 
ARI (Crofton, 1975). Data from Ghana (Ghana Health Project Assessment Team, 1981) 
indicate that over 94% of the 52 days lost per case of ARI are due to mortality rather 
than disability. Particularly in the setting of developing countries, where case fatality 
ratios are high and access to services limited, the bulk of costs attributable to ARI will be 
indirect costs due to mortality. Although no such estimates are available for the 
developing world, there is also likely a relatively greater toll due to ARI in these settings 
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where children experience growth deficits, malnutition, and resulting learning disabilities 
due to recurrent ARI episodes. Although these indirect costs of ARI are difficult to 
quantitate, they likely greatly reduce the potential productivity of those affected. 
3. Lowering the Incidence of ARI 
3.1 Elements of the Preventive Strategy 
Possible preventive approaches to reduce ARI morbidity and mortality include: 1) 
immunization and 2) alteration of other risk factors which predispose to ALRI. It has 
been estimated that deaths due to the four vaccine preventable respiratory diseases 
(measles, diphtheria, pertussis and tuberculosis) may account for up to 25% of the total 
mortality among children under five in the developing world. Although the data are 
adequate to support the use of immunization in the control of ARI, the limitations of 
current knowledge regarding the feasibility and effectiveness of other preventive 
strategies are, for the moment, a barrier to their use in programs to reduce ARI 
morbidity and mortality. 
The available data do not yet justify the design and implementation of programs to 
reduce environmental and nutritional risk factors for ARI control. However, the 
evidence does suggest that such approaches may be effective. Several of those which 
might be considered for inclusion in ARI control programs have been included in the 
following discussion of potential preventive interventions. Those for which evidence of 
feasibility and effectiveness are strongest are included in a comparative model of cost- 
effectiveness, which is summarised in table 3.3. It is important to recognize, however, 
that the actual benefits for these interventions would be broader than those calculated, 
since each would reduce morbidity and mortality due to many health problems beyond 
ARI alone. Sources for the data used and the methods for calculating the cost- 
effectiveness estimates are specified in appendix A. 
Measles Immunization. Operational problems in maintaining the "cold chain" for 
handling the measles vaccine are a frequent barrier to maintaining vaccine viability and 
efficacy. WHO has estimated the efficacy of the vaccine to be 90% in the absence of any 
breaks in the cold chain (Keja, 1988). Because of variability in study design and 
alterations in vaccine viability due to handling, measured vaccine efficacies may vary 
broadly, although Hull (1983) achieved an 89% efficacy in The Gambia. 
Considerable controversy surrounds the issue of immunization strategy for measles. 
Studies with the currently available (Schwartz) vaccine have demonstrated that residual 











































































































































































































































































































































































































































































































































































































































































































































































life. Available data regarding age-specific seroconversion and measles incidence rates 
suggested that immunization at nine months of age would prevent the maximal number 
of cases (EPI, 1982). These data were the basis for the WHO recommendation of one 
dose of measles vaccine to be given between 9 and 12 months of age. 
Yet, in many countries, 20 to 45% of measles cases occur among infants before nine 
months of age, when they are most vulnerable to measles mortality. It had been 
suggested that "herd immunity" achieved with adequate immunization coverage among 
older infants and children may serve to reduce the infection rate among younger infants 
(Black, 1982; Heymann, 1983). Recent evidence, however, suggests that in areas of high 
population density, there is no shift in the age distribution of cases or reduction in 
incidence greater than the level of vaccination coverage (Taylor, 1988; Dabis, 1988). 
Particularly in the urban areas of Africa, the increased transmission rates may lower the 
optimal age for immunization (Taylor, 1988; McLean, 1988). 
In view of these and other findings, the Expanded Programme on Immunization (EPI) of 
WHO has endorsed the use of the newer high potency vaccines at six months of age in 
countries where measles is a significant problem among infants under nine months of 
age. The Edmonston-Zagreb (EZ) strain measles vaccine and other such high potency 
preparations have demonstrated more promising immunogenicity and protection in 
younger infants than the vaccines in current use, most of which are lower-titer derivatives 
of the Edmonton-Enders strain. The new EZ vaccine has demonstrated higher 
seroconversion rates among infants in Mexico (Sabin, 1983, 1984), The Gambia (Whittle, 
1988), and Bangladesh (Khanum, 1987), as well as in several unpublished studies (WHO, 
1990), without serious adverse reactions. Similar titers to those obtained with Schwartz 
vaccine at nine months are observed at 4-6 months with EZ vaccine in the developing 
country trials. 
Ongoing studies of the efficacy, optimal dose, non-parenteral routes of administration (in 
order to overcome residual maternal antibodies), and booster response to the new 
vaccines will help to further refine immunization policies in the near future. More 
studies are needed to explore the cost-effectiveness of a two-dose schedule, such as initial 
measles immunization with the third DTP dose (followed by a second dose at six to 
twelve months of age). High drop-out rates, which are a major barrier to the success of 
immunization programs, also argue in favor of using earlier opportunities for 
immunization, even if children are less than the ideal age for achieving seroconversion or 
optimum protection. Some investigators, however, have raised the concern that earlier 
immunization may interfere with antibody response at the time of revaccination (Stetler, 
1986; Wilkins, 1979; Linnemann, 1982). 
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Pertussis Immunization. The vaccine for pertussis is delivered together with the 
diphtheria and tetanus vaccines (DTP). Pertussis vaccine efficacy for the fully (i.e., 3 
doses) immunized child has been recently questioned, but is estimated at 70-90% in the 
industrialized world (Church, 1979; Koplan, 1979) and 50-90% in developing countries 
(WHO/EPI, 1985). Like for measles, however, transmission rates in endemic areas are 
such that many children are infected and most deaths occur prior to the usual age of 
completed immunization. 
Pertussis immunization coverage in some industrialized countries has fallen off in the last 
fifteen years due primarily to concern about associated adverse neurological effects, most 
notably encephalopathy (Brahmans, 1986), although there is also some controversy about 
the vaccine's effectiveness (Fine, 1987). Outbreaks of pertussis have been observed in 
Great Britain, Japan and Sweden, where policy changes or public opinion have led to a 
reduction of immunization coverage. However, even with the current preparation, the 
benefit of the vaccine far outweighs the risk of adverse effects (Koplan, 1979; Cherry, 
1984). Accelerated research has led to the development of acellular pertussis vaccines 
which offer hope in the near future for both improved efficacy and fewer adverse effects 
(Miller, 1991). 
Pneumococcal Immunization. The pneumococcal vaccine licensed for use in the 
U.S. is composed of the purified polysaccharide extracted from 23 of the 84 types of 
Streptococcus pneumoniae. These capsular subtypes are responsible for approximately 
90% of invasive pneumococcal disease in the U.S. However, over 30% of blood culture 
isolates from patients with pneumonia in developing countries have been pneumococcal 
serotypes which are not included in the current vaccine (Ghafoor, 1990; Mastro, 1991). 
In addition, the vaccine induces little immunity in children under 18 months of age, who 
are most vulnerable to mortality due to pneumococcal infections. 
Studies in the U.S. have suggested a 50-80% efficacy in preventing bacteremia and 
pneumonia among adults with the currently available vaccine. Results of studies among 
the very elderly or chronically ill (Simberkoff, 1986) and among children under 18 months 
have been less encouraging. The vaccine has also been tested in Papua New Guinea, 
which reports one of the highest proportions of ALRI due to pneumococcal infections at 
up to 50%. Clinical trials there (Riley, 1986) among children 6-59 mos of age have 
shown a 50% reduction in ARI-specific mortality rates during periods of one to five years 
after immunization. However, there appears to have been no reduction in pneumonia 
incidence and there is little evidence to suggest that the vaccine was immunogenic in the 
younger age groups. The cause of the mortality reduction is, therefore, not clear and the 
results need to be replicated in other developing countries. Also of potential interest was 
the finding that infants of mothers immunized during their last trimester had a 32% 
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lower rate of pneumonia (Riley, 1981). Such "passive" protection of infants while they 
await completion of immunization series deserves further investigation. 
H. influenzae Vaccine. Like pneumococcal vaccine, which is also a polysaccharide 
vaccine, the current H. influenzae vaccine has limited immunogenicity in infant and young 
children. The vaccine is made from H. influenzae type b (Hib) polysaccharide, since this 
type accounts for virtually all of invasive disease in the industrialized world. Protective 
efficacy measured in children over 24 months of age has ranged from 0% to 90% 
(Granoff, 1986; Harrison, 1987; Black, 1988; Gilsdorf, 1988), based on prevention of 
invasive disease (mainly meningitis and bacteremia). The efficacy of the Hib vaccine in 
reducing pneumonia morbidity and mortality cannot be estimated from US data, since 
the frequency of pneumonia due to Hib is too low. 
An increase in early cases after Hib immunization has been variously ascribed to 
unmasking of latent infection or shortening of the incubation period, perhaps due to 
transient post-vaccination reductions in antibody levels (Black, 1988). One study 
(Osterholm, 1987) actually calculated an increased risk of H. influenzae infection of 45%, 
leaving the protective effect of Hib vaccine in some doubt. 
The newer Hib conjugate vaccines, which link Hib antigens to protein carriers, show 
improved immunogenicity in children under two and hold greater promise for preventing 
H. influenzae disease in the very young. Although experience with use of diphtheria 
toxoid as a conjugate has been mixed, tetanus toxoid carriers may be more effective 
(Ward, 1990; Siber, 1990; Eskola, 1990). Formulations for developing countries will need 
to include additional types (i.e., non-b and non-serotypable H. influenzae) which are not 
a prominent cause of invasive disease in the industrialized world (Funkhouser, 1991). 
Recent studies in Papua New Guinea (Weinberg, 1990), Pakistan (Ghafoor, 1990), and 
The Gambia have shown that approximately half of all invasive H. influenzae disease is 
due to non-serotypable or non-b strains. 
The costs of the current conventional Hib vaccine is US$2.19 per dose, while the 
conjugate vaccine is $14 per dose. Hay (1987) compared the costs and benefits of 
rifampin prophylaxis of exposed contacts to immunization with the currently available 
unconjugated vaccine. Vaccination was predicted to be the most cost-effective strategy 
with a calculated overall net savings of US$64.8 million, in the setting of an anticipated 
social cost of US$1.94 billion for H. influenzae disease in the 1984 birth cohort. Because 
of the paucity of data on Hib vaccine effectiveness in developing countries, no estimates 
of cost-effectiveness have been included in table 3.3. 
Other Immunizations. Vaccination to induce immunity to organisms which cause 
ARI mortality is clearly an effective preventive intervention. There is good evidence to 
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support the use of vaccines against measles and pertussis, both in the documented public 
health importance of these problems and the effectiveness of immunization. Although 
the expected impact of diphtheria vaccine is difficult to predict due to the lack of 
information regarding diphtheria morbidity and mortality, marginal costs of including the 
vaccine with pertussis and tetanus (in DTP vaccine) are nearly negligible. 
Effective vaccines against the viral causes of pneumonia and bronchiolitis would likely 
avert additional mortality. However attempts to develop effective vaccines against the 
two most important causes of mortality, RSV and parainfluenza viruses, have been 
frustrating. Recently, however, the mechanism for the adverse hypersensitivity responses 
to RSV antigens has been identified, so that purified antigen and recombinant vaccines 
currently under development should offer greater hope for these important cause of 
respiratory mortality (Pringle, 1987). Influenza vaccines have been effective in preventing 
infections, particularly among the elderly, but the "antigenic drift" which characterizes 
these viruses makes vaccine production and distribution more costly. Such immunization 
programs for adults have also been poorly received and achieve limited coverage. 
Environmental and Nutritional Risk Reduction. Alteration of other documented 
and suspected risk factors for ARI mortality, such as poor nutritional status (including 
LBW, poor infant feeding practice, undernutrition, and vitamin A deficiency) and 
exposure to smoke (including active and passive cigarette smoking and smoke due to 
organic fuel cookfires), have been suggested as additional strategies for the prevention of 
ARI deaths. Although for some of these risk factors the associations are strong, there 
are few studies which support the feasibility and effectiveness of programs using these 
interventions to prevent ARI. The data are strongest for promotion of breastfeeding and 
reduction of malnutrition. 
3.2 Good Practice and Actual Practice: Are There Gaps? 
Correct case management is the central strategy of WHO's Programme for the Control 
of Acute Respiratory Infections, however, one of the four objectives is "to reduce the 
incidence of acute lower respiratory infection." Although intervention to alter some of 
the non-specific risk factors for ARI (table 3.2) is an intriguing possibility for prevention 
of pneumonia, immunization remains the only strategy known to be effective in the 
prevention of morbidity and mortality due to ARI. 
Even this proven technology, however, has not been fully exploited to prevent ARI 
mortality. As of 1988, 97 countries had an Expanded Programme on Immunization (EPI) 
(Keja, 1988), but many of these have subnational coverage, often neglecting the neediest 
children in the most remote areas. Vaccination efforts are most appropriately integrated 
with the primary health care system, avoiding duplication of necessary management, 
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supervisory, training, and logistical resources. Immunization campaigns, while they result 
in high short-term coverage, may compromise sustainability and divert resources from the 
development of the rest of the primary health care infrastructure. 
Global coverage estimates for children immunized during the first year of life are 50% 
for measles and 55% for the DTP series of three doses (Keja, 1988), although figures are 
considerably lower in Africa. Barriers to achieving improved coverage with the EPI 
vaccines include difficulties with supply and management systems and the prat tical 
problems of maintaining the cold chain. High "drop-out" rates for immunizati )n series 
are partly due to limitations of resources for social mobilization, the opportun,ty costs to 
the family in obtaining immunizations, failure of health workers to profit from, clinic visits 
by giving immunizations (Keja, 1988), and adverse effects of current vaccine preparations. 
There has been increasing attention, especially in Africa, to the frequent problem of 
reuse of syringes and needles. These unsafe immunization practices introduce the risk of 
transmission of blood-borne diseases such as hepatitis and AIDS. 
Efforts to prevent ARI mortality through reduction of the prevalence of malnutrition and 
LBW are hampered by the obvious social, economic and political barriers to 
development. Promotion of appropriate infant feeding practice, including breastfeeding, 
represents an opportunity to reduce ARI morbidity and mortality that deserves greater 
emphasis. Although research must continue to improve preventive technologies for the 
major causes of ARI mortality, ARI control programs for the near future will rely 
,)rincipally on improved case management to reduce ARI mortality. 
4. Case Management 
4.1 Elements of the Case Management Strategy 
WHO's ARI Control Programme has taken the lead in promoting intervention to address 
the problem of ARI in children. The primary objective of the program is the reduction 
of ALRI mortality through effective case management. Secondary objectives include the 
reduction of 1) the severity and complications of acute upper respiratory tract infections, 
2) the inappropriate use of antibiotics and other drugs for the treatment of ARI, and 3) 
the incidence of pneumonia. To improve the case management of pneumonia, WHO has 
developed guidelines for standard treatment at first level and referral health facilities and 
at the community level. 
In countries with a high incidence of bacterial pneumonia (generally those with an infant 
mortality rate greater than 40 per 1000), pneumonia may be relatively reliably diagnosed 
on the basis of simple clinical criteria alone. For any child under five with cough or 
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difficult breathing, tachypnea (rapid breathing) appears to be the best single predictor of 
pneumonia and the need for antibiotic treatment (Shaun, 1982; Cherian, 1988; Campbell, 
1988; 1989a; 1989b; Lucero, 1990). In view of the variation of normal respiratory rates 
with age, WHO guidelines recommend a threshold of 60 or more per minute in young 
infants (under two months), 50 or more for older infants (2 to 11 months), and 40 or 
more for children one to four years of age (WHO, 1990b). Chest indrawing (retraction 
of the lower part of the chest wall on inspiration) detected in children two months to 4 
years of age, indicates the presence of severe pneumonia requiring hospitalization. The 
algorithms used for diagnosis and treatment of childhood pneumonia, including additional 
criteria for referral for hospitalization, are summarized in figures 3.1 and 3.2 (WHO, 
1991a). Any of four inexpensive antibiotics may be recommended for the home care of 
uncomplicated pneumonia, including cotrimoxazole (trimethoprim-sulfamethoxazole), 
amoxycillin, ampicillin, and procaine penicillin. 
Although wheezing (including asthma) is managed within this algorithm, there are 
separate guidelines for care of sore throats and ear infections. All cases receive general 
supportive care, including fluids, continued feeding, treatment of fever, and clearing of 
nasal or ear discharge as needed. Although these findings require further confirmation, 
studies in Pakistan have suggested that such supportive measures may actually reduce the 
likelihood of progression of uncomplicated coughs and colds to life-threatening 
pneumonias (Khan, 1990). 
There is no doubt about the importance of bacterial pneumonia as a cause of mortality 
or about the effectiveness of antimicrobials in reducing case-fatality ratios. But to 
address concerns whether periperal health care workers with limited training could 
identify and treat cases appropriately, several intervention studies were conducted to test 
the algorithm for case-management in an operational setting in several developing 
countries. These and another study conducted in Jumla, Nepal, were recently reviewed 
(WHO, 1988a). Although each of the studies suffered from design flaws and/or 
confounding due to simultaneous introduction of other interventions, taken as a whole 
they present strong evidence of the efficacy of case management. It was found that ARI- 
specific mortality declined by an average of 41.6% (range 18-65%), while overall 
mortality was reduced in the same five study areas by an average of 22.2% (range 11.5- 
40%). These studies, for which further details are presented in table 3.4, confirmed the 
feasibility and efficacy of providing case management of ARI through peripheral health 
workers with limited training. 
These results compare favorably with earlier more theoretical calculations of the 
expected effectiveness of ARI case management interventions. For example, Tugwell 
(1985) assumed an efficacy of cotrimoxazole in treatment of community-acquired ALRI 
of 80%, a diagnostic accuracy of 80% by the health workers, a correct treatment rate of 
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Figure 3.1 
THE YOUNG INFANT 
(AGE LESS THAN 2 MONTHS) 
Stopped feeding well, 
SIGNS: Convulsions, 
Abnormally sleepy or 
diffcult to wake, 
Stridor in calm child, 
* Wheezing, or 
* Fever or low body temperature. 
CLASSIFY AS: VERY I 
SEVERE DISEASE 
TREATMENT: 
Refer URGENTLY to hospital. 
Keep young infant warm. 
Give first dose of an antibiotic. 
SIGNS: Severe chest indrawing, 
or 
Fast breathing 
(60 per minute or MORE). 
No severe chest indrawing, 
and 
No fast breathing 
(LESS than 60 per minute). 
CIASSIFYAS: SEVERE PNEUMONIA 
NO PNEUMONIA: 
COUGH OR COLD 
Refer URGENTLY to hospital. Advise mother to give the following 
home care: 
TREATMENT. Keep young Infant warm. Keep young infant warn. 
Breast-feed frequently. 
Give fist dose of an antibiotic. Clear nose M it 
Interferes with feeding. 
(If referral is not feasible, treat Return quickly It 
with an antibiotic and follow Breathing becomes difficult. 
closely.) 
Breathing becomes fast. 
Feeding becomes a problem. 




AGE 2 MONTHS UP TO 5 YEARS 
SIGNS: 
CLASSIFY AS: 
Not abfa b drklk, 
Conarblor», 
Aboon * sbw or 
dNApAt to wake, 




Refer URGENTLY b hospital. 
Give first dose of an anUblotic. 
TREATMENT: Treat fever, k Pra 
Treat wheaft If present 
M cerebral melada Is possible, 
give an anftelerlal. 
SIGNS: Chest khdrawing. No chest kdawa No crest khdrawkhg, 
and and 
pt atao reeurrent wheezkhQ, Fast best" No fast breafty 
0o directly to (50 per mkrAe or more i child (Less Men SO per m hAe 1 child 
Tiwt WvheezWgrl 2 mont+s up b 12 morthe: 2 months up to t2 widen; 
40 per mkhule or mare llddd Lou Men 40 per n*eAs 1 did 
l2 will up to 5 yews). 12 monlb up to 5 yews). 
NO PNEUMONIA 
CLASSIFYAS. SEVERE PNEUMONIA PNEUMONIA 
COUGH OR COLD 
TREATMENT. "Refer URGENTLY to ho*W. Advbe mdw to give home care. ' 
Give first dose of an w0lotk. Give an ardmoft . Assess and trash m problere or 
Treat favor, N present Trod favor, k piew sorethe M pl e" (saacham 
Trod wfheezkhg, If p "pt Tro wheaft a present. ' Assess end treat other problems 
Advise mother to give home are. 
(It referral Is not Maslble, test ' Advise mother to rahrm with child In 
Treat favor K present 
with an antibiotic and Now 2 days for reassassthhent, or sar6er , 
dos*.) I the child Is getup worse. Treat wheaft d present 
Reassess In 2 days a child who Is taking an antbo0c for pneurnonla: 
WORSE IMPROVING 
SIGNS: Not" to ddr 6490111111s lower. 
Has chest 'dowlig. 
THE SAME Lass favor. 
Has other danger signs. Eaft beter. 






































































































































































































































































































































































































































































































































































































































































































































90%, 80% patient compliance with the medication regimen, and 80% access to 
appropriate treatment, calculating an expected program effectiveness of 37%. 
Lessons learned from the case management intervention trials must be taken into 
account in program design and selection of research priorities. For example, the Jumla 
study documented a mean duration of fatal episodes of pneumonia of 3 1/2 days 
(Daulaire, personal communication, 1990). Under these circumstances, active 
surveillance by health workers is unlikely to detect an adequate proportion of cases. ARI 
control programs must rely on families to detect signs and symptoms of-pneumonia and 
bring suspected cases to a health worker for evaluation and treatment. Reductions in 
deaths due to diarrhea were observed in Jumla, where only pneumonia cases were 
treated (WHO, 1988a), raising the important question of the impact of antibiotic 
treatment on concurrent infections such as diarrhea or malaria. 
Few operational programs for ARI case management have measured cost per case 
treated or death averted. The figures which are available have been obtained in research 
settings, where expenditures may not be representative. Costs per case treated in the 
Philippines have been estimated at US$5.15 and $4.37 (Brenzel, 1990). Costs per death 
averted have ranged from US$200 in Indonesia to $350 in Nepal (Brenzel, 1990). Using 
a model to estimate cost-effectiveness outlined in appendix A, we have calculated an 
expected cost per death averted of US$926, and a cost per discounted healthy year of life 
saved of US$37. 
4.2 Good Practice and Actual Practice: Are There Gaps? 
By the end of 1990, 54 countries had prepared plans of operation for ARI control 
programs and 47 had functioning programs (WHO, 1991b). Eighteen additional 
countries had designated a national program manager and issued technical guidelines for 
case management. Therefore, a total of 59 countries, most of which are in the Americas 
and Western Pacific, had taken some steps to establish a national ARI control program. 
Yet it is clear that the "greater intrinsic complexity" (WHO, 1990b) of the management 
of ARI will present great challenges in the implementation of control programs. The 
significant operational problems encountered in immunization and diarrheal disease 
control programs, for example, are likely to be dwarfed by the obstacles to successful 
implementation of an ARI control program. Appropriate case management requires that 
each of many difficult conditions be met, including the design and comunication of 
culturally appropriate and effective health education for family recognition of suspected 
pneumonia, prompt presentation to an effectively trained and carefully supervised health 
worker, correct diagnosis and selection of treatment, development and maintenance of 
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reliable logistical systems to assure adequate supplies of antibiotics, family compliance 
with appropriate instructions for care, and access to competent referral care as required. 
These prerequisites for effective case management of pneumonia are inextricably linked 
to the the basic infrastructure for primary health care. Although ARI control may be 
introduced as another "vertical" program, it is less conveniently addressed outside the 
context of the health care delivery system as a whole. Strengthening of systems to reduce 
ARI mortality therefore requires a more comprehensive approach to improving access 
and quality of care. 
It will be important, for example, to rationalize the use of antibiotics for other health 
problems in order to assure adequate supplies will remain to treat cases of pneumonia. 
Even when basic antibiotics are unavailable in peripheral health centers, the presence of 
antibiotics in remote markets provides evidence of the effectiveness of informal systems 
of distribution. Such sales of antimicrobials in the informal sector likely leads to their 
inappropriate use in even more than the 50 to 95% of cases in which inappropriate use is 
observed in health centers (Chaulet, 1982; Hossain, 1982; Gutierrez, 1986). Reduction of 
the inappropriate use of these supplies may actually avert pneumonia deaths at no 
increased cost, both through increasing effective use and reducing adverse effects and the 
evolution of antimicrobial resistance (Stansfield, 1990). Although the feasibility of 
labelling of antibiotics in special packages (as solely for use in the treatment of 
pneumonia in children) is being assessed (WHO, 1990b), the inevitable discovery of the 
alternative uses of these powerful pharmaceuticals will likely render such devious 
practices ineffective. 
Another obstacle to be anticipated is the resistance of physicians to empowering other 
health care workers with limited training to diagnose and treat with antibiotics. Narain 
(1987), for example, has presented evidence that over 90% of physicians do not agree 
that non-physician health workers should be provided with antibiotics to treat children 
suffering from pneumonia. Vigilance will also be required to prevent commercial drug 
companies from exploiting new markets by extracting inflated prices for basic 
pharmaceutical supplies. 
Many countries will require assistance in the development of laboratory capability to 
assure correct selection of antibiotics (at least in tertiary care facilities), particularly for 
referral patients who have failed treatment with first-line antibiotics, through basic 
bacterial cultures and tests for antibiotic sensitivity. These capabilities are also required 
to maintain the necessary surveillance for the emergence of significant antibiotic 
resistance patterns, as is evidenced by the alarming resistance to commonly used 
antimicrobials in several countries (El Mouzam, 1988; Lataorre, 1988; Mastro, 1991). 
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Donor agencies must recognize these gaps when allocating resources for ARI control 
program development. 
Although the historical lack of donor support in this area has also been an important 
obstacle to ARI control, the donor community has recently shown increased interest in 
strengthening ARI case management. Reduction in ARI deaths by 25% was included 
among targets established for the 1990s by the WHO/UNICEF Joint Committee on 
Health Policy. This commitment is only beginning to be reflected in increased levels of 
national, bilateral, and multilateral funding to ARI control programs. 
5. Priorities for ARI Control 
5.1 Priorities for Resource Allocation 
The many national health plans which emphasize the priority of interventions to reduce 
infant and child mortality cannot long ignore ARI, which is often a major cause of this 
mortality. Global commitment to addressing this problem was reflected in the adoption, 
at the World Summit for Children in September 1990, of a resolution to reduce deaths 
due to ARI by one third during the final decade of this century (UNICEF, 1991). In 
view of the efficacy of the vaccines and of antibiotic therapy for pneumonia, it is 
probable that over half of ARI deaths could be averted using only the currently available 
technologies of immunization and improved case management. Breastfeeding promotion 
and reduction of the prevalence of malnutrition are also likely to be cost-effective in 
reducing mortality due to ARI. Interventions for the promotion of breastfeeding, 
reduction of malnutrition, and immunization with EPI vaccines will have a broader 
impact on child survival through their effectiveness in prevention of mortality due to 
diseases other than ARI. These three interventions, along with appropriate case 
management, should be given high priority for implementation, particularly in countries 
with high infant mortality. Such a combined curative-preventive approach is likely to be 
the most effective as a strategy to reduce mortality (Mosley, 1988). 
National ARI control programs should be developed or accelerated according to the 
guidelines recently refined by WHO's Programme for the Control of Acute Respiratory 
Infections. Intervention studies have provided adequate evidence among children under 
five that improved case management of ARI will reduce mortality due to ARI and, 
possibly, overall mortality in that population. As WHO has pointed out (WHO, 1988x), 
"there is no technical justification in delaying any further the expansion of ARI control 
programmes as an essential component of child survival efforts, and with the same 
priority attached to the Expanded Programmes on Immunization (EPI) and the diarrheal 
disease control (CDD) programmes." Although most countries have active EPI 
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programs, these programs must also be strengthened to assure improved coverage 
(Poore, 1988). 
Referral care of pneumonia in persons who have responded poorly to antibiotic 
treatment requires adequate laboratory support to perform bacteriologic cultures, 
organism identification, and antibiotic sensitivities. Any national ARI control program 
must, therefore, allocate adequate resources to competently monitor antibiotic resistance 
in at least one national reference center. Ability to conduct vaccine trials will also 
depend on laboratory capability in the identification of specific serotypes for the major 
pathogens. 
5.2 Research Priorities 
During program design and implementation, high priority should also be assigned to 
establishing a strong evaluation or applied research component to aid in assessing the 
effectiveness of operational programs, refining program priorities and addressing the 
many questions which remain regarding optimal strategies for prevention and case 
management. WHO recently reviewed research priorities for ARI control (WHO, 1989; 
1990c), preparing a list which is adapted and presented in table 3.5. 
Additional research needs to be addressed include the development and validation of 
survey techniques for detection of ARI episodes and pneumonia deaths for use in 
program evaluation. Studies are also needed to determine the impact of antibiotic use 
on the incidence and mortality of other diseases (especially malaria and diarrhea) and 
the sociocultural factors which modulate the effectiveness of programs. Vaccine research 
issues, in addition to those detailed in table 3.5, should include additional efficacy trials of 
the newer measles vaccines and two-dose schedules of administration. 
Another issue for operational research will be the effect of current program emphasis on 
children under 5. Promoting the recognition of the need and increasing the demand for 
health services will be essential to the success of ARI control programs. Although the 
opportunity for impact is greatest among the program's target group, it will be important 
to assess the benefits and costs to national programs which attempt to reserve health 
workers' attentions and antibiotic supplies for children at the perceived expense of the 
communities' adult decision-makers and opinion leaders. 
Opportunities to explore mechanisms to achieve financial sustainability may be limited 
for the immunization interventions designed to prevent ARI. For the curative care 
provided in the case management of ARI, however, it will be important to explore 
mechanisms for cost recovery, such as health insurance schemes, taxation, or user fees to 
enhance the financial sustainability of national programs. 
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(adapted from WHO/ARI/89.4 and 90.7) 
RESEARCH PRIORITIES FOR ACUTE RESPIRATORY INFECTION CONTROL 
EPIDEMIOLOGIC RESEARCH 
* Assess the effectiveness of interventions and programs to modify the risk of 
pneumonia, especially through reduction of exposure to biomass fuel emissions. 
* Document the epidemiology of invasive strains of Haem philus influenzae and 
Streptococcus pneumoniae, to guide the development of effective vaccines. 
* Define the relative prevalence and etiologies of pneumonia, sepsis and meningitis 
in less immunocompetent groups such as young infants (less than three months of 
age) and undernourished children. 
CASE MANAGEMENT (CLINICAL) RESEARCH 
* Identify the signs and symptoms which indicate the need for hospital care. 
* Evaluate the performance of the treatment protocol, including for wheezing, at 
first level referral facilities. 
* Explore the most effective ways to define and teach the reliable distinction 
between clinical presentations of pneumonia and malaria, and to determine the 
efficacy of cotrimoxazole in treatment of malaria. 
* Define the clinical features and optimal treatment of serious bacterial infection 
(pneumonia, sepsis, and meningitis) in young infants (< three months of age). 
* Determine the special needs of undernourished children, including the clinical 
features and causes of pneumonia and the optimal treatment for these children. 
SOCIAL SCIENCE RESEARCH 
* Examine cultural and other factors which determine families' ability to recognize 
signs of pneumonia, seek appropriate care and comply with treatment regimens. 
* Identify optimally effective strategies for the design of appropriate health 
education programs for ARI control, including for the modification of risk factors 
for pneumonia. 
VACCINE AND DIAGNOSTICS DEVELOPMENT RESEARCH 
* Develop inexpensive, simple, and reliable diagnostic technologies which will aid in 
counting respiratory rate and determining the etiology of pneumonias, such as by 
identifying viral or bacterial antigens in urine or blood. 
* Perform field trials of the available polysaccharide pneumococcal vaccine and of 
conjugate vaccines for H. influenzae type b and for nonserotypable H. influenzae. 
RSV and parainfluenza viruses when available. 
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Appendix A 
SOURCES OF DATA AND METHOD USED 
TO OBTAIN COST-EFFECTIVENESS ESTIMATES SUMMARISED IN TABLE 33 
Since no prospective data are available for the effectiveness of preventive interventions in 
the reduction of ARI mortality among children under five, the estimates used in table 3.3 
are obtained primarily from retrospective observations of relative risk. These figures, 
therefore, represent indirect estimates of the potential efficacy of the intervention rather 
than a measure of effectiveness achieved in an operational setting. Cost estimates for 
these preventive interventions are also obtained indirectly, through review of data for 
similar programs. Cost estimates for case management interventions are similarly derived 
from data available from other programs with similar interventions. 
Estimates were made assuming a standard population of one million persons, with 15% 
of the population being children under five (approximately 3% infants) and 8% mothers 
of children under five. Estimates of cost and effectiveness for immunization interventions 
are made using a coverage range of 45% to 90%, as used by Feachem (1983). "Most 
likely" values for immunization interventions are calculated assuming an immunization 
coverage of 80%, the target specified for UNICEF's goal of "Universal Childhood 
Immunization". Calculations of deaths averted were based on pre-intervention ARI- 
specific mortality rates of 5 to 20 per thousand (with a "most likely" value of 10/1000), 
which yields an expected 750 to 3000 (most likely 1500) deaths among the 150,000 
children under five in the standard population of one million. 
The effect of implementing of multiple interventions to prevent ARI mortality is unlikely 
to be simply additive. Many children who die with ARI suffer from several risk factors, 
such as the malnourished child who dies of pneumococcal pneumonia during or within 
one month of an episode of measles. One possibility is that such "competing risks" of 
mortality (Mosley, 1986) may operate on the same children, so that prevention of one 
potentially mortal event may only leave children vulnerable to other causes of so-called 
"replacement mortality" (WHO/EPI, 1987b). 
Another possibility is that prevention of ARI is actually synergistic with other preventive 
interventions through reducing the cumulative contributions to the "frailty" (Mosely, 1985) 
of the child, such as is observed in the growth faltering with recurrent infection. An 
example of the potential for synergism among interventions has been suggested by recent 
observations of a reduction of diarrheal disease mortality in a program which treats only 
childhood pneumonias (WHO, 1988a). 
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The calculations presented below consider only the short-term effects of these 
interventions upon mortality. It is not known whether the longer term impact of these 
preventive and curative interventions would be augmented by reduction in the frailty of 
these children, or offset by replacement mortality. Because of these theoretical problems 
and the many operational problems associated with predicting the effects of multiple 
health interventions, the figures presented in table 3.4 are of use primarily as estimates of 
the relative cost-efficacy of interventions when implemented alone to reduce ARI 
mortality. All costs are stated in US dollars. 
ExQanded Program on Immunization. Most of the ARI mortality prevented by the EPI 
vaccines is due to measles and pertussis. Feachem and Koblinsky (1983) estimate that 
measles immunization between the ages of 9 and 12 months, with an ideal efficacy of 
90% and a coverage of between 45 and 90% can avert 44-64% of measles cases. 
Anticipating the improved efficacy of the higher potency vaccines and immunization 
before nine months of age, the upper limit of the proportion of cases averted was 
adjusted to 80%. Since pertussis vaccine has a similar ideal efficacy (WHO, 1985), it is 
assumed that a similar proportion of cases would be averted at the same coverage rates 
of 45% to 90% Therefore, for pertussis and measles, an efficacy range of 44% to 80% 
has been used for the model, with an intermediate "most likely" value of 65%. 
It has been estimated that up to 25% of ARI mortality may be preventable using current 
EPI vaccines. Mortality among children under 5 due to measles-associated ARI 
accounted for approximately 20% of all ARI mortality (1.8/1000 out of 9.1/1000) in 17 
study areas during case management trials for WHO (WHO, 1988a). It is therefore 
assumed that 20% to 25% of ARI mortality would be addressed through use of current 
EPI vaccines. An expected ARI-specific mortality reduction of 8.8% to 20% ("most 
likely" 14.6%) may be calculated using these figures. These estimates are comparable to 
the ARI mortality reduction figures of 5% to 20% calculated by Singhi (1987) and 
Steinhoff (1987), although Clemens (1988) observed a 22% protective efficacy of measles 
vaccine for respiratory deaths in Bangladesh. Based on the expected numbers of deaths 
of 750 to 3000, the number of deaths averted may be calculated to range from 66 to 600, 
with a "most likely" value of 219. 
The cost per child served for EPI immunization interventions to prevent ARI mortality is 
calculated as that portion of the cost of delivering all EPI vaccines which is proportional 
to the benefit achieved in averting ARI deaths. Tetanus is the only non-ARI EPI disease 
which is a significant cause of infant and child mortality. Since tetanus accounts for up to 
40% of the overall mortality prevented through EPI vaccines, 60% ($9.08) of the $15.13 
average cost per fully immunized child (Brenzel, 1989) was ascribed to ARI prevention. 
The cost per ARI death averted (achieving 
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coverage levels of 45-90% among the 30,000 infants in the target age group) may, 
therefore be calculated at $409 to $1857, with a "most likely" value of $995. 
Pneumococcal Immunization. The efficacy of pneumococcal vaccine, particularly among 
the youngest children, has not been clearly demonstrated in the developing world. The 
reported efficacy in adults of 0-80% and the efficacy of 69% noted among children in the 
U.S. suggest a range of 0-70%. However, since the vaccine is less immunogenic among 
children under two (approximately 40% of under fives), an estimated 20% of invasive 
pneumococcal infections in developing countries are caused by serotypes not included in 
the vaccine, and assuming a 45 to 90% coverage (as for the EPI vaccines), the expected 
disease-specific mortality reduction may be in the range of 0% to 30%. An intermediate 
"most likely" value of 15% was selected. 
Since pneumococcal disease accounts for less than one third to one half of pneumonia 
(IOM, 1986), the maximal reduction in pneumonia mortality with the presently available 
vaccine is likely approximately 0% to 15%, with a "most likely" value of 7%. Although 
this range does not include the greater reductions in ARI-specific mortality observed 
among children 6-59 months of age in Papua New Guinea (Riley, 1986), the 
epidemiology of pneumococcal disease in that country is probably not typical of that in 
most developing countries. Based on the 750 to 3000 expected deaths among under 
fives, the number of deaths averted may be calculated to be from 0 to 450, with a most 
likely value of 105. 
The estimated cost per child vaccinated is calculated by reducing the current price of the 
vaccine (US$9.69 per dose) by one half (assuming that the cost will be reduced for the 
international market in exchange for waiver of liability and once research and 
development costs are recovered) and adding the cost per dose delivered for the EPI 
vaccines (US$2.44 average), since the costs of EPI vaccines (US$0.04-US$0.15 per dose) 
are small relative to the cost of the pneumococcal vaccine. The resulting estimated cost 
per dose delivered of US$7.28 suggests that (at coverage levels of 45% to 90%) the cost 
per death averted would be greater than US$437, with a most likely value of $1664. 
Breastfeeding Promotion. Reductions in incidence and case-fatality ratios for pneumonia 
noted with breastfeeding (Chandra, 1979; LePage, 1981; Victora, 1987) suggest that a 
50% to 80% ARI-specific mortality reduction might be realized among breastfed infants. 
However, the protective effect is observed only below 12 months of age (approximately 
20% of under fives), and actual prevalence of breastfeeding among infants is generally 
over 80% in high-mortality countries, such that only approximately 4% of under fives 
would benefit from a program to promote breastfeeding. Even assuming 100% 
effectiveness in changing breastfeeding practice, ARI-specific mortality reduction among 
children under five observed with breastfeeding promotion would be only 2% to 3.2% 
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(with a "most likely" value of 2.8% based on Victora's observation of over 70% reduction 
in relative risk), resulting in an estimated 15 to 96 ("most likely" 42) deaths averted 
through promotion of breastfeeding. 
The average cost of a program to promote breastfeeding has been estimated at US$5.00 
(Feachem, 1984; 1986; Phillips, 1987) per mother. Even if targeting of services is only 
adequate to identify the subset of 50% of the mothers who are "at risk" of not 
breastfeeding, the population served might be reduced to half of the mothers with infants 
(8000 in the standard population of one million). The estimated cost per ARI death 
averted for an educational program to promote breastfeeding may be calculated to be 
US$417 to US$2667, with a "most likely" value of $952. 
Reduction of Malnutrition. Expected mortality reduction with improved nutritional status 
was estimated based on the two- to 20-fold higher mortality observed in malnourished 
children (Kielmann, 1978; Herrero, 1983; Tupasi, 1988). Successful improvement of 
nutritional status might be expected to result in a 50% to 95% reduction in the risk of 
ARI-mortality among malnourished children. A "most likely" value of 80% reflects the 
modest estimate of a five-fold higher relative risk of pneumonia deaths among these 
malnourished children. Since 70 to 90% of all pneumonia deaths occur among the 
malnourished, expected ARI specific mortality reductions of 35% to 85% ("most likely" 
value 64%) might be expected with successful improvement of nutritional status. Support 
for these estimates is provided by the results of a nutritional intervention program in 
Tanzania (UNICEF, 1988b), where a 23% reduction (from 48% to 37%) in the 
prevalence of mild to moderate malnutrition (<80% weight for age) and a 60% 
reduction (from 5% to 2%) in the prevalence of severe malnutrition (<60% weight for 
age) were associated with a 64% reduction in ARI-specific mortality. The expected 
number of ARI deaths averted at this level of effectiveness would be 263 to 2550, with a 
"most likely" value of 960, although these figures would be highly dependent on the initial 
prevalence of undernutrition. 
The lower estimate for the cost of such a program to improve nutritional status is based 
on expenditures.of US$15 per year per malnourished child under five (Ashworth, 1986), 
although effective targeting of the malnourished children would be difficult to achieve. 
The Joint Nutrition Support Program (JNSP) in Tanzania (UNICEF, 1988b) estimated its 
costs at $10.05 per child per year (from both national and donor sources), with the 
addition of $9.00 per child for "start-up" costs. Annual costs may be estimated at 
US$11.85 per child if the initial program "start-up" costs can be spread over five years. 
The cost, therefore, per million population would likely be between $810,000, for the 
targeted program for the expected 54,000 (36%, based on 1990 UNICEF data) children 
who are malnourished, and $1,777,500, to serve all of the 150,000 using the model of the 
Tanzania program. The use of the "most likely" value of $1,500,000 reflects the better 
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credibility of the figures from Tanzania. Final evaluation of the JNSP Program may, 
however, yield costs per child as low as $2.50 per year (UNICEF, personal 
communication, 1991). The cost per death averted is calculated, however, with the less 
favorable preliminary figures to be $697 to $3080, with a "most likely" value of $1563. 
Case Management. There is little information available to date regarding the costs of 
operational programs for ARI case management where effectiveness has also been 
assessed. Cost per child treated and death averted may, however, be estimated from 
drug costs and costs for implementing other programs with similar interventions. The 
following model was constructed to provide an estimate of the cost of case management 
for cost-effectiveness calculations: 
The cost per million population of appropriate case management for ARI is equal to the 
sum of. 1) the cost of health education or sensitization regarding program interventions 
(E), 2) the cost of outpatient care for coughs and colds (U*Cu*(V+M+Z*A)), where U 
= the incidence of coughs and colds (per 1000), Cu = the coverage or proportion of 
coughs and colds in the community which come to the attention of the health care 
system, V = the average cost of an ambulatory care visit or consultation, M = the cost of 
non-antimicrobial medications, Z = the proportion of URI cases inappropriately treated 
with antimicrobials, and A = the average cost of a course of antimicrobials), 3) the cost 
of outpatient care for pneumonia (P*Cp*(M+A+N*V)), where P = the incidence of 
pneumonia (per million), Cp = the coverage or proportion of pneumonia cases in the 
community which are diagnosed and treated appropriately (i.e., given antimicrobials with 
or without other medications for supportive care), and N = the number of consultations 
per episode), and 4) the cost of inpatient care for severe pneumonia (S*Cs*(H+V)), 
where S = the incidence of severe pneumonia (per million), Cs = the coverage or 
proportion of severe pneumonia in the community which is diagnosed and treated 
appropriately (i.e., given antimicrobials and referred for more specialized care), and H = 
the cost of referral, generally including inpatient hospital care). Therefore, the total cost 
of case management per million population is: 
E . + U*Cu*(V+M+Z*A) + P*Cp*(M+A+N*V) + S*Cs*(H+V) 
Clearly, each of the variables in the model has a range of values. Calculations of cost 
and effectiveness were made using a range of values, including a "most favorable" (in 
terms of impact on cost-effectiveness), "least favorable", and "most likely". The specific 
values used for each variable are listed in table 3.6 and the "most likely" values for the 
derived variables in table 3.7. 
Sensitization costs (E) are derived from estimates by Phillips (1987), including a low cost 
option using person to person communications at $1 per mother (in groups of 10), and a 
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SUMMARY OF VARIABLES AND RANGE OF VALUES FOR MODEL OF 








E Sensitization cost $800,000 $400,000 $80,000 
V Cost of one outpatient consultation $2.00 $1.50 $1.00 
M Cost per episode of non-antimicrobial $3.20 $0.08 0 
A 
pharmaceuticals 
Cost per episode of antimicrobials $7.00 $0.80 $0.16 
H Cost of inpatient or referral care $135 $45 $6 
N Average number of visits per episode 2 1.5 1 
U Cases of coughs and colds 1,500,000 1,050,000 600,000 
P Cases of uncomplicated pneumonia 5000 7500 10,000 
S Cases of severe or complicated 1000 1500 2000 
pneumonia 
Proportion of URI cases seen and 0.10 0.05 0.02 
z 
treated by health worker 
Proportion of URI cases 0.50 0.10 0 
Cp 
inappropriately treated with 
antibiotics 
Proportion of uncomplicated 0.10 0.40 0.70 
C$ 
pneumonia cases appropriately 
. diagnosed and treated 
Proportion of severe pneumonia cases 0.40 0.65 0.90 
F 
appropriately diagnosed and treated 
Case fatality ratio for untreated 0.10 0.13 0.20 p 
FS 
uncomplicated pneumonia 
Case fatality ratio for untreated severe 0.25 0.35 0.50 
R 
or complicated pneumonia 
Percent reduction in mortality with 0.60 0.80 0.90 















































































































































































































































































































high cost program including use of mass media at $10 per mother (assuming that there 
are 80,000 mothers of children under five). The intermediate cost program 
estimate of $5 per mother equals those estimates used for breastfeeding promotion and 
weaning education programs (Feachem 1986; Phillips, 1987). 
The cost of one outpatient consultation (V) has been derived from figures for diarrheal 
disease and immunization consultations (Phillips, 1987), assuming that the time spent by 
the health worker is comparable. A high cost figure of $2.00 reflects average costs per 
visit in many Latin American countries, the intermediate cost of $1.50 and low cost of 
$1.00 are more typical of costs per outpatient consultation in Asia and Africa. Costs for 
non-antimicrobial pharmaceuticals (M), which are optional in the management of ARI, 
are estimated at zero for the low cost figure, $0.08 for intermediate costs typical of five 
days supply of a locally made cough syrup, and $3.20 to reflect the often larger 
expenditures on non-antimicrobial pharmaceuticals in many developing countries (Quick, 
1988). 
The values selected for the cost per episode of antimicrobials (A) were based on 
UNICEF (1988) prices for a five day course for a 10 kg child. These figures were 
doubled to include costs for transport, packaging and dispensing these medications. 
Basic prices included a low cost figure of $0.08 for five days of cotrimoxazole for a 10 kg 
child, $0.40 for the intermediate figure (Bates, 1987; Quick, 1988), and $3.50 for 
intramuscular penicillin and chloramphenicol for the high cost program. Costs for 
referral care with hospitalization (H) used in the model include a high cost figure of $135 
(three days at $45 per day) from Brazil (Shepard, unpublished data, 1989), an 
intermediate figure of $45 (three days at $15 per day) from Rwanda (Shepard, 
unpublished data, 1989), and a low cost figure of $6 (three days at $2 per day). The 
number of visits per episode (N) will ideally be two, although a lower value of one is 
used, as some programs require no follow-up visit (WHO, 1988a). The intermediate 
figure of 1.5 reflects probable level of compliance with the recommended follow-up visit. 
The values used for high, intermediate and low incidence of coughs and colds among 
children under five (U) are ten, seven and four per child per year (Datta Banik, 1969; 
Kamath, 1969; Friej, 1977; Foreit, 1987), yielding the numbers of episodes specified in 
table 3.6 among the 150,000 children under five in the standard population. For 
pneumonia incidence (P), the figures selected were 100, 50, and 25 per 1000 (Riley, 1981; 
Pio, 1982; WHO, 1989b). For severe pneumonia (S), the figures are 25, 10, and 5 per 
1000 (Chen, 1980; Riley, 1983; WHO, 1984b). 
Although ideally fewer than 2% of coughs and colds will be brought to the attention of 
and diagnosed by the health worker (Cu), a likelier figure is 5%, while over 10% has 
been observed in some programs (Foreit, 1987). The cost of inappropriate treatment of 
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coughs and colds with antibiotics is included in the model, since this may be a source of 
excess costs and of potential savings in improving case management practices (Stansfield, 
1990). The percent of coughs and colds seen by a health worker and treated 
inappropriately with antibiotics (Z) will ideally be zero, although in many programs up to 
half of such cases receive antimicrobials. A "most likely" value of 10% should be 
achieveable with careful training and supervision of health workers. A study in Lesotho 
(Redd, 1990) found that 6% to 15% of practitioners (before retraining using WHO 
guidelines) reported that they would treat a cough or cold with antimicrobials, so it is 
likely that observed rates of inappropriate use of antimicrobials would exceed these 
reported rates. 
For pneumonia coverage (Cp), the figures selected for the model are 70%, 40%, and 
10%. WHO estimates that 12% of all childhood pneumonias were treated with 
antibiotics in 1990, and projects increases to 40% in 1995 and 60% by 2000 (WHO, 
1991b). Although there are no good data from operational settings, it has been 
estimated that from 40% to 90% (with a "most likely" value of 65%) of severe 
pneumonias may be seen and diagnosed by a health care worker (Cs). Incidence and 
coverage figures selected for URI and pneumonias yield proportions which are 
pneumonia (among all ARI cases presenting in health facilities) of 4% ("least favorable") 
to 50% ("most favorable"), with a "most likely" value of 17%. These figures reflect such 
measurements made in operational settings (WHO, 1990c; Foreit, 1987; Quick, 1988). 
The incidence (P and S) and case-fatality ratios (F and Fs) specified in table 3.4 yield 
ARI-specific mortality values of 511000, 10/1000, and 20/1000, reflecting probable levels 
of ARI mortality (UNICEF, 1990; WHO, 1991a) among under fives in middle mortality, 
high mortality, and very high mortality countries. Numbers of deaths averted were, 
therefore, calculated based on expected numbers of deaths of 750 (511000), 1500 
(10/1000), and 3000 (5011000) for moderate, high, and very high mortality countries, 
respectively. The range of assumptions for treatment efficacy (R) includes 90% for a 
highly efficacious program (Berman, 1985), 80% for the intermediate level of efficacy 
(IOM, 1986), and 60% for the lower level of efficacy, such as may be seen in settings 
where compliance is poor. 
Using the values for each variable specified in table 3.6, the additional variables defined 
in table 3.7 were derived. Calculation of the cost per capita of ARI case management 
(C) using these figures yields a most likely value of $0.54, or $541,877 for the sample 
poulation of one million. The ranges for total cost (of $220,000 to $940,000) and for the 
cost-effectiveness figures used in table 3.3 reflect values obtained from the sensitivity 
analysis, which is summarized in table 3.8, obtained by varying one parameter at a time. 
The sensitivity analysis data indicate that program costs and cost effectiveness are most 



































































































































































































































































































































































































































































































































































































(as measured by deaths averted) is lowest with low values for coverage of uncomplicated 
pneumonia, and highest when the incidence of severe pneumonia is high. 
A "most likely" value for cost-effectiveness for ARI case management of $926 (per death 
averted) was calculated. Use of the extreme figures for incidence and case-fatality ratios 
(rather than varying one parameter at a time, as in the sensitivity analysis), such as may 
be observed in high and low mortality countries, yields cost and effectiveness figures 
specified in table 3.9. These figures underline the fact that interventions to improve ARI 
case management are of highest priority in the countries with high overall and ARI- 
specific infant and child mortality rates. These estimates are higher than the estimates of 
$350 per death averted obtained in a field study in Nepal and $131 per death averted 
obtained in the Philippines (JSI, unpublished data). 
Calculations of cost per discounted healthy year of life saved are made using a life 
expectancy of 50 years, an average age at death of two years, and a discount rate of 3% 
per annum. Ranges for the intermediate variables and a summary of the cost- 
effectiveness calculation are presented in table 3.3, in a format for comparison with the 




COST-EFFECTIVENESS OF ARI CASE MANAGEMENT 
FOR LOW AND HIGH MORTALITY COUNTRIES 
LOW MORTALITY HIGH 
MORTALITY 
Cost per Capita of ARI Care $0.52 $0.56 
Cost per Target Population $3.49 $3.61 
Deaths Averted 338 1160 
Cost per Death Averted $1152 $483 
Cost per Discounted Healthy $46 $19 
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